Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Inclusion Criteria: * 18 years of age or older * Biopsy-proven (consisting of ≥ 12 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core (TRUS or/and mpMRI/TRUS fusion), Gleason score (3+3) or predominant Gleason pattern 3 (3+4), ≤ 33% of biopsy cores, and ≤50% involvement of any biopsy core (Participant meets all criteria for Active Surveillance as determined by MD) * Willing to start or continue on active surveillance * Baseline/screening serum PSA \<10 ng/mL * No other prior treatment for PCa, including focal therapy * ECOG performance status 0-1 * No history of renal or hepatic disease, including history of hepatitis B and C * Meet hematological eligibility parameters (Neutrophil count ≥ 1,200/mm3 (≥1.2 k/μL), Stable platelet count ≥ 75,000/mm3 (≥ 75k/μL) Hepatic and renal function eligibility parameters, serum total Bilirubin ≤ULN (ULN: 1.2 mg/dl) (or ≤3.0 mg/dL for patients with Gilbert's syndrome), AST or ALT \<1.5x ULN and Serum creatinine ≤1.5 x ULN * Willing to abstain from consumption of any supplements containing GTC * Willing to restrict tea consumption to less than three (3) servings of hot tea or three (3) servings of iced tea per week * Willing to discontinue current vitamin/mineral supplement use and use one provided by study * Willing to take study agent or placebo at the dose specified with meals. Exclusion Criteria: * Have had prior treatment for PCa by surgery, irradiation, local ablative (i.e., cryosurgery or hig…